Clovis testing cancer drug on U.S. patient

BOULDER – Clovis Oncology Inc. has tested its first U.S. patient in its TIGER2 cancer study, the company announced this week.

Boulder-based Clovis (Nasdaq: CLVS)  is in the process of testing CO-1686, an oral targeted inhibitor of mutant forms of an epidermal growth-factor receptor for the treatment of non-small-cell lung cancer, according to the company. The testing is referred to as TIGER2.

“The CO-1686 data observed to date have been highly consistent, including the growing evidence of a lengthy duration of benefit and the tolerability profile of the drug,´ said Patrick J. Mahaffy, president and CEO of Clovis, in a statement.

SPONSORED CONTENT

Select your Republic Services residential cart now!

In preparation for Republic Services becoming the primary provider of residential recycling, yard trimmings, and trash, residents should now select the best cart size and service schedule for their household needs.

The company plans on filing a new drug application by mid-2015, after several more months of testing.

Testing of CO-1686 first occurred in Japan in the first quarter.